Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody, Arlene Naranjo, Collin Van Ryn, Alice L. Yu, Wendy B. London, Barry L. Shulkin, Marguerite T. Parisi, Sabah E.Noor Servaes, Mitchell B. Diccianni, Paul M. Sondel, Julia G. Bender, John M. Maris, Julie R. Park, Rochelle Bagatell
Dive into the research topics of 'Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial'. Together they form a unique fingerprint.